XML 51 R41.htm IDEA: XBRL DOCUMENT v3.24.3
Collaborations and Other Arrangements - Narrative (Details) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 9 Months Ended
Jul. 31, 2023
Jun. 30, 2023
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Proceeds from sale of product rights       $ 530.9 $ 1,604.3
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Olanzapine Portfolio          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Proceeds from sale of product rights $ 1,050.0        
Additional cash proceeds $ 305.0        
Revenue recognized     $ 1,420.0   1,420.0
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Baqsimi          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Proceeds from sale of product rights   $ 500.0      
Additional cash proceeds   $ 125.0      
Milestone payment received       $ 450.0  
Revenue recognized         $ 579.0
Royalty Agreement Terms | Olumiant®          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Collaborative arrangement, rights and obligations percent (up to)       20.00%  
Milestone Payments, Sales-based | Olumiant®          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Potential achievements       $ 100.0  
Milestone Payments, Sales-based | Ebglyss          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Potential achievements       1,250.0  
Milestone Payments, Sales-based | Ebglyss | Roche          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Potential achievements       1,030.0  
Milestone Payments, Sales-based | Orforglipron | Chugai          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Potential achievements       250.0  
Milestone Payments, Development and Regulatory | Orforglipron | Chugai          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Potential achievements       $ 140.0